Percutaneous Radiofrequency Ablation with Multiple Electrodes for Medium-sized Hepatocellular Carcinomas
Overview
Authors
Affiliations
Objective: To prospectively evaluate the safety and short-term therapeutic efficacy of switching monopolar radiofrequency ablation (RFA) with multiple electrodes to treat medium-sized (3.1-5.0 cm), hepatocellular carcinomas (HCC).
Materials And Methods: In this prospective study, 30 patients with single medium-sized HCCs (mean, 3.5 cm; range, 3.1-4.4 cm) were enrolled. The patients were treated under ultrasonographic guidance by percutaneous switching monopolar RFA with a multichannel RF generator and two or three internally cooled electrodes. Contrast-enhanced CT scans were obtained immediately after RFA, and the diameters and volume of the ablation zones were then measured. Follow-up CT scans were performed at the first month after ablation and every three months thereafter. Technical effectiveness, local progression and remote recurrence of HCCs were determined.
Results: There were no major immediate or periprocedural complications. However, there was one bile duct stricture during the follow-up period. Technical effectiveness was achieved in 29 of 30 patients (97%). The total ablation time of the procedures was 25.4 ± 8.9 minutes. The mean ablation volume was 73.8 ± 56.4 cm(3) and the minimum diameter was 4.1 ± 7.3 cm. During the follow-up period (mean, 12.5 months), local tumor progression occurred in three of 29 patients (10%) with technical effectiveness, while new HCCs were detected in six of 29 patients (21%).
Conclusion: Switching monopolar RFA with multiple electrodes in order to achieve a sufficient ablation volume is safe and efficient. This method also showed relatively successful therapeutic effectiveness on short-term follow up for the treatment of medium-sized HCCs.
Li S, Zhou F, Zhang Y, Xu S, Wang Y, Cheng L Med Phys. 2024; 52(1):113-130.
PMID: 39387846 PMC: 11700007. DOI: 10.1002/mp.17450.
Radiofrequency ablation with sine and square electrical waveforms to enhance ablation range.
Won D, An J, Kim J, Park Y, Lee S, Kim H Front Bioeng Biotechnol. 2024; 12:1450331.
PMID: 39234269 PMC: 11372458. DOI: 10.3389/fbioe.2024.1450331.
Han S, Sung P, Park S, Kim J, Hong H, Yoon J Gut Liver. 2024; 18(5):789-802.
PMID: 39223081 PMC: 11391139. DOI: 10.5009/gnl240350.
Han S, Sung P, Park S, Kim J, Hong H, Yoon J J Liver Cancer. 2024; 24(2):131-144.
PMID: 39210668 PMC: 11449576. DOI: 10.17998/jlc.2024.08.04.
Han S, Sung P, Park S, Kim J, Hong H, Yoon J Korean J Radiol. 2024; 25(9):773-787.
PMID: 39197823 PMC: 11361797. DOI: 10.3348/kjr.2024.0550.